Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GB-0669 in Healthy Subjects

NCT07050511 is registered in ClinicalTrials.gov with Generate Biomedicines as lead sponsor.

NCT NCT07050511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GB-0669 in Healthy Subjects
Lead sponsor
Generate Biomedicines
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2023
Completion date
November 22, 2024
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov-2